Home Cart Sign in  
Chemical Structure| 459868-92-9 Chemical Structure| 459868-92-9

Structure of Rucaparib phosphate
CAS No.: 459868-92-9

Chemical Structure| 459868-92-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rucaparib phosphate is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding affinity to eight other PARP domains.

Synonyms: PF-01367338 phosphate; AG-014699 phosphate; PF-01367338

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rucaparib phosphate

CAS No. :459868-92-9
Formula : C19H21FN3O5P
M.W : 421.36
SMILES Code : O=C1NCCC2=C(C3=CC=C(CNC)C=C3)NC4=C2C1=CC(F)=C4.O=P(O)(O)O
Synonyms :
PF-01367338 phosphate; AG-014699 phosphate; PF-01367338
MDL No. :MFCD17010269
InChI Key :FCCGJTKEKXUBFZ-UHFFFAOYSA-N
Pubchem ID :9931953

Safety of Rucaparib phosphate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P280-P305+P351+P338-P310

Related Pathways of Rucaparib phosphate

epigenetics
DNA

Isoform Comparison

Biological Activity

Target
  • PARP

    PARP, Ki:1.4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
GBM12 cells 1 µM and 3 µM 14 days To evaluate the efficacy of Rucaparib in combination with TMZ, results showed that Rucaparib significantly enhanced the efficacy of TMZ. Mol Cancer Ther. 2015 Dec;14(12):2735-43.
MDCKII cells 2 µM 60 min To evaluate the accumulation of Rucaparib in MDCKII cells, results showed that Rucaparib is a substrate for both MDR1 and BCRP1 efflux pumps. Mol Cancer Ther. 2015 Dec;14(12):2735-43.
MEFs 100 nM 2 weeks To evaluate the sensitivity of MEFs to Rucaparib, results showed that Brca1CC/Δ11 cells formed more colonies in the presence of 100 nM Rucaparib, but significantly fewer colonies at 1000 nM Rucaparib. Mol Cell. 2020 Jun 4;78(5):951-959.e6.
T47D 1 μM 24 h To detect the effect of Rucaparib on DNA damage, the results showed that Rucaparib induced more DNA damage. Cell Death Dis. 2024 Dec 18;15(12):898.
MDA-MB-231 1 μM 24 h To detect the effect of Rucaparib on NAD⁺ levels, the results showed that Rucaparib effectively prevented NAD⁺ depletion Cell Death Dis. 2024 Dec 18;15(12):898.
CD4+ T cells 10 µM 12 h Inhibition of PARP enzyme activity, reducing IL-17 release and ROS levels Cell Rep Med. 2023 Sep 19;4(9):101157.
GEA PDX-derived primary cells 1.25 –40μM 6 days To evaluate the growth inhibitory effect of Rucaparib on GEA PDX-derived primary cells, results showed that cells with BRCA2 mutations were sensitive to Rucaparib Cancer Res. 2023 May 15;83(10):1699-1710.
MDA-MB-231 cells 15 µM 4, 8, 24 h To study the effect of Rucaparib on the transcriptomic dynamics of MDA-MB-231 cells, revealing transcriptomic changes at different time points. Mol Syst Biol. 2021 Apr;17(4):e10060.
IB114 1.488 μM 72 h To study the antiproliferative activity of Rucaparib on IB114 cells, IC50 value was 1.488 μM J Hematol Oncol. 2017 Apr 11;10(1):84.
IB115 1.104 μM 72 h To study the antiproliferative activity of Rucaparib on IB115 cells, IC50 value was 1.104 μM J Hematol Oncol. 2017 Apr 11;10(1):84.
IB111 1.364 μM 72 h To study the antiproliferative activity of Rucaparib on IB111 cells, IC50 value was 1.364 μM J Hematol Oncol. 2017 Apr 11;10(1):84.
IB133 58.08 μM 72 h To study the antiproliferative activity of Rucaparib on IB133 cells, IC50 value was 58.08 μM J Hematol Oncol. 2017 Apr 11;10(1):84.
IB134 40.88 μM 72 h To study the antiproliferative activity of Rucaparib on IB134 cells, IC50 value was 40.88 μM J Hematol Oncol. 2017 Apr 11;10(1):84.
IB136 31.35 μM 72 h To study the antiproliferative activity of Rucaparib on IB136 cells, IC50 value was 31.35 μM J Hematol Oncol. 2017 Apr 11;10(1):84.
IB112 29.5 μM 72 h To study the antiproliferative activity of Rucaparib on IB112 cells, IC50 value was 29.5 μM J Hematol Oncol. 2017 Apr 11;10(1):84.
IB128 12.036 μM 72 h To study the antiproliferative activity of Rucaparib on IB128 cells, IC50 value was 12.036 μM J Hematol Oncol. 2017 Apr 11;10(1):84.
93T449 19.2 μM 72 h To study the antiproliferative activity of Rucaparib on 93T449 cells, IC50 value was 19.2 μM J Hematol Oncol. 2017 Apr 11;10(1):84.
GBM U251 cells 0.2, 0.5, 1, 2, 5, 10, 25, 50, 100 μM 96 h To evaluate the antiproliferative effect of Rucaparib on GBM U251 cells, results showed that Rucaparib inhibited cell proliferation in a dose-dependent manner with an IC50 value of 14.36 μM. Cell Death Dis. 2021 May 26;12(6):546.
GBM U87MG cells 0.2, 0.5, 1, 2, 5, 10, 25, 50, 100 μM 96 h To evaluate the antiproliferative effect of Rucaparib on GBM U87MG cells, results showed that Rucaparib inhibited cell proliferation in a dose-dependent manner with an IC50 value of 15.00 μM. Cell Death Dis. 2021 May 26;12(6):546.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice GBM12 flank xenograft model Intraperitoneal injection 1 mg/kg Every 28 days × 3 cycles, daily for 5 days To evaluate the efficacy of Rucaparib in combination with TMZ in the GBM12 flank xenograft model, results showed that Rucaparib significantly prolonged the time to tumor regrowth. Mol Cancer Ther. 2015 Dec;14(12):2735-43.
Mice Brca1CC/Δ11 mice Oral 200 mg/kg Twice daily for 5 days To evaluate the tolerability of Rucaparib in Brca1CC/Δ11 mice, results showed that Rucaparib treatment led to a reduction in blood lymphocytes, but was unaffected and mice survived. Mol Cell. 2020 Jun 4;78(5):951-959.e6.
Mouse BRCA1-deficient mouse ovarian tumor cell line BR5 Oral 150 mg/kg Twice daily for 5 days, 2 days off, then 5 days To evaluate the sensitivity of BRCA1-deficient tumors to PARPi, results showed that BRCA1-deficient tumors were sensitive to PARPi and exhibited replication tract lengthening after treatment Mol Cell. 2021 Aug 5;81(15):3128-3144.e7.
NSG mice MOLT4 tumor xenograft model Intraperitoneal injection 40 mg/kg Twice daily for 16 days To evaluate the anti-tumor efficacy of 180055 in BRCA1-mutated tumor models, the results showed that 180055 significantly inhibited tumor growth with fewer side effects. Cell Death Dis. 2024 Dec 18;15(12):898.
Mice IB115 cell xenograft model Intraperitoneal injection 10 mg/kg Five times per week for 3 weeks To evaluate the antitumor effect of Rucaparib on the IB115 cell xenograft model, the results showed that Rucaparib significantly prolonged progression-free survival J Hematol Oncol. 2017 Apr 11;10(1):84.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00457470 Diabetes Mellitus|Diabetic Ret... More >>inopathy Less << PHASE2 WITHDRAWN - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.37mL

0.47mL

0.24mL

11.87mL

2.37mL

1.19mL

23.73mL

4.75mL

2.37mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories